Articles tagged "HLA antibodies"

2016 American Transplant Congress
Clinical Significance of Non-HLA Antibodies in the Development of Microcirculation Inflammation in Allograft Tissue After Kidney Transplantation.
J. Min,^1,3 H. Lee,^2,3 B. Chung,^1,3 E.-J. Oh,^2,3 C. Yang.^1,3
¹Division of Nephrology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea; ²Department of Laboratory Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea; ³Transplant Research Center, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
The aim of our study is to determine the clinical significance of pre-transplant non-HLA antibodies, mainly those targeting the angiotenin II type I receptor (AT1R)…
2016 American Transplant Congress
Comparison of Efficacy and Safety of a 4-Month Post-Renal Transplant Dose Reduction of Tacrolimus.
P. Gatault,¹ N. Kamar,² M. Buchler,¹ C. Colosio,³ D. Bertrand,⁴ A. Durrbach,⁵ L. Albano,⁶ J. Rivalan,⁷ M. Essig,⁸ Y. Le Meur,⁹ N. Bouvier,¹⁰ B. Charpentier,⁵ E. Thervet,¹¹ L. Rostaing,² Y. Lebranchu.¹
¹Service de Transplantation rénale, CHRU, Tours, France; ²Service de Transplantation Rénale, CHU, Toulouse, France; ³Service de Transplantation Rénale, CHU, Reims, France; ⁴Service Transplantation Rénale, CHU, Rouen, France; ⁵Service de Transplantation Rénale, APHP, Kremlin Bicêtre, France; ⁶Service de Transplantation Rénale, CHU, Nice, France; ⁷Service de Transplantation Rénale, CHU, Rennes, France; ⁸Service de Transplantation Rénale, CHU, Limoges, France; ⁹Service de Transplantation Rénale, CHU, Brest, France; ¹⁰Service de Transplantation Rénale, CHU, Caen, France; ¹¹Service de Néphrologie, APHP, Centre Européen Georges Pompidou, Boulogne-Billancourt, France.
Introduction. The aim of the study was to determine the efficacy and safety balance of 2 different doses of tacrolimus extended-release (TacER) in kidney transplant…
2016 American Transplant Congress
Preformed Antibodies Against AT₁R and EDNRA Correlate with Rejection Post-Transplant.
A. Gareau,¹ C. Wiebe,^1,2 D. Pochinco,² I. Gibson,³ D. Rush,¹ P. Nickerson.^1,2,4
¹Internal Medicine, University of Manitoba, Winnipeg, MB, Canada; ²Diagnostic Services of Manitoba, Winnipeg, MB, Canada; ³Pathology, University of Manitoba, Winnipeg, MB, Canada; ⁴Immunology, University of Manitoba, Winnipeg, MB, Canada.
Studies have investigated the potential pathogenic effects of non-HLA antibodies (Ab), with a few reporting that Ab against the angiotensin II type 1 receptor (AT1R)…
2016 American Transplant Congress
Diffuse Extent of Peritubular Capillaritis in Late Antibody Mediated Rejection Is Associated with More Severe Chronic Allograft Damage.
Z. Kikić,¹ F. Eskandary,¹ H. Herkner,² R. Oberbauer,¹ G. Bond,¹ H. Regele,³ G. Böhmig,¹ N. Kozakowski.³
¹Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria; ²Emergency Medicine, Medical University of Vienna, Vienna, Austria; ³Institute of Clinical Pathology, Medical University of Vienna, Vienna, Austria.
Peritubular capillaritis (ptc) is a widely accepted histologic criterion of antibody-mediated rejection (ABMR), and while the ptc score is incorporated in current diagnostic recommendations, the…
2016 American Transplant Congress
Donor-Specific Antibody Is a Major Independent Predictor of Accelerated Heart Allograft Vasculopathy (CAV).
M. Bories,¹ S. Varnous,² C. Lefaucheur,³ P. Rouvier,² R. Guillemain,¹ P. Bruneval,¹ J. Duong Van Huyen,⁴ A. Loupy.⁴
¹European Georges Pompidou Hospital, Paris, France; ²La Pitié Salpêtrière Hospital, Paris, France; ³Saint-Louis Hospital, Paris, France; ⁴Necker Hospital, Paris, France.
Introduction The role of circulating DSA in addition to traditional cardiovascular risk factors, in the development of accelerated CAV have not been demonstrated. We investigated…
2016 American Transplant Congress
A Virtual Crossmatch Algorithm That Mimics the Sensitivity of Flow Cytometric Crossmatch.
P. Rao, D. Deo, C. Rhodes, D. King, P. Bowe, J. Napoleon, I. Okere.
NJ Sharing Network, New Providence, NJ.
Aim: The new Kidney Allocation System has increased requests for virtual crossmatches (VXM) to predict the possibility of a negative donor specific crossmatch. This study…
2016 American Transplant Congress
Long-Term Follow-Up of Renal Transplant Recipients (RTR) Treated with IVIG for De Novo Donor Specific Antibodies (DSA).
R. Knight,¹ S. Patel,¹ J. Loucks-DeVos,² S. Kuten,¹ A. Gaber.¹
¹Houston Methodist Hospital, Houston, TX; ²Kansas University Medical Center, Kansas City, KS.
Intravenous immune globulin (IVIG) may be beneﬁcial for pre-emptive treatment of de novo DSA in RTR without biopsy-proven acute rejection (AR). Herein, we present long-term…
2016 American Transplant Congress
Impact of Early Red Blood Cell Transfusion After Kidney Transplantation on De Novo HLA Sensitization in the Setting of Antithymocyte Globulin Induction.
T. Jouve,^1,2 G. Rigault,^1,2 B. Janbon,¹ R. Tetaz,¹ N. Terrier,¹ D. Masson,³ L. Rostaing,^1,2 P. Malvezzi.¹
¹Nephrology and Kidney Transplantation Unit, Grenoble University Hospital, Grenoble, France, Metropolitan; ²Grenoble Alpes University, Grenoble, France, Metropolitan; ³Etablissement Francais du Sang, Grenoble, France, Metropolitan.
Introduction:HLA specific antibodies detection (HSA) and that of Donor Specific Antibodies (DSA) were revolutionized by the introduction of solid phase assays (Luminex®), therefore making these…
2016 American Transplant Congress
Kidney Transplantation with Strong Preformed Donor-Specific Antibodies: Impact of C1q-Binding Ability.
J. Malheiro,¹ S. Tafulo,² S. Santos,¹ M. Costa,¹ L. Martins,¹ L. Dias,¹ A. Henriques.¹
¹Nephrology, CHP, Porto, Portugal; ²CSTP, Porto, Portugal.
HLA-incompatible kidney transplantation is associated with worse outcomes given the presence of donor-specific anti-HLA antibodies (DSA). Our aim was to investigate the association between preformed…
2016 American Transplant Congress
Impact of the New Kidney Allocation System (KAS) on Transplant Rates & Outcomes in Broadly-HLA Sensitized (HS) Patients Transplanted After Desensitization (DES).
A. Vo,¹ X. Zhang,² S. Williamson,¹ K. Myers,¹ N. Reinsmoen,² J. Choi,¹ J. Kahwaji,¹ A. Peng,¹ R. Villicana,¹ S. Jordan.¹
¹Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; ²HLA Laboratory, Cedars-Sinai Medical Center, LA, CA.
Introduction: HS patients not desensitized (DES) receiving transplants are at risk for ABMR. DES improves transplant rates, but is limited to donor availability. Implementation of…